**PATENT** 



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Black, Jr.

Appl No.:

Not Assigned

Group Art Unit:

Not Assigned

Filed:

Concurrently Herewith

Examiner:

Not Assigned

For:

COMPOSITIONS AND METHODS FOR ACTIVATING GENES OF INTEREST

September 20, 2001

**Box Patent Application** Commissioner for Patents Washington, DC 20231

## INFORMATION DISCLOSURE STATEMENT CITATION UNDER 37 C.F.R. § 1.97

Sir:

Attached is a list of documents on form PTO-1449. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

All items are attached except those that were supplied in parent Application No. 09/446,402 filed December 20, 1999. Since the benefit of this application was claimed under 35 U.S.C. 120, no copies need to be furnished in accordance with 37 C.F.R. 1.98(d); however, copies will be furnished on request.

Respectfully submitted,

Registration No. 45,941

Customer No. 00826 ALSTON & BIRD LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200

Fax Raleigh Office (919) 862-2260

"Express Mail" Mailing Label Number EL868637407US Date of Deposit: September 20, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner for Patents, Washington, DC 20231.

Martinez

Nora C. Martinez

Cultural for forms 1440 A /DTO						C 1 VOYZ				
Substitute for form 1449A/PTO					-	Complete if Known				
TATEODA ( MYON)					A	Application Number Not Assigned			-0	
INFORMATION									PTO	
DISCLOSURE						ling Date	Concurrently Herewith		<u>S</u>	
STATEMENT BY APPLICANT					$\Gamma$ Fi	rst Named Inventor	Black, Jr.			
					Gı	roup Art Unit	Not Assigned	<u></u>		
(Use as many sheets as necessary)					E	kaminer Name	Not Assigned		ğ	
Sheet	Sheet 1		of 1		Aı	torney Docket Number	35722/238390(5722-2A)			
							-			
U. S. PATENT DOCUMENTS										
			U.S. Patent Document				Date of Pages, Columns, Line			
Examiner	Cite	Kind Co				Name of Patentee or Applicant	Publication of	Where Relevant Passages of Relevant Figures Appear		
Initials*	No.1	Num	Number (if know		nown)	Of Cited Document	Cited Document MM-DD-YYYY	ment		
	!	<u> </u>					MINI-DD-1111			
FOREIGN PATENT DOCUMENTS										
Foreign Patent Document							Date of	Pages, Columns, Lines,		
Examiner	Cite	Kind Co				de Name of Patentee or	Publication of	Where Relevant	T <sup>6</sup>	
Initials	No.	Office	Office <sup>3</sup> Number <sup>4</sup> (if know		nown) 5	5 Applicant of Cited Document	Cited Document	Passages or Relevant Figures Appear		
							MM-DD-YYYY	rigues Appear		
NON PATENT LITERATURE DOCUMENTS										
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item										
Examiner	Cite								T	
Initials	No.		city and/or country where published.							
	1	/	ANDERSON, "Human Gene Therapy," Nature, April 30, 1998, pp. 25-30, Vol. 392							
	2	2 BRANC		ANCH, "A Good Antisense Molecule is Hard to Find," TIBS 23, February 1998, pp. 45-50, Elsevier						
	1	Science Ltd.								
***************************************	<del>-   3</del>		OI EM AN et	EMAN et al., "The Use of RNA's Complementary to Specific mRNAs to Regulate the Expression of						
	ľ		Individual Bacterial Genes," Cell, June 1984, pp. 429-435, Vol. 37							
***************************************										
	4	, ,		_	gineering of the m-RNA-Interfering Complementary RNA Immune System Against					
			Viral Infection," <i>Proceeding of the National Academy of Sciences, USA</i> , October 1986, pp. 7726-7730, Vol. 83							
***************************************	5		VERMA et al., "Gene TherapyPromises, Problems and Prospects," <i>Nature</i> , September 18, 1997, pp. 239-							
		242, Vol. 389		•	, , , , , , , , , , , , , , , , , ,					
						The state of the s				
Evaminar							Doto			

RTA01/2103818v1

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number.

<sup>&</sup>lt;sup>2</sup> See attached Kinds of U.S. Patent Documents.

<sup>&</sup>lt;sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>&</sup>lt;sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>&</sup>lt;sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>&</sup>lt;sup>6</sup> Applicant is to place an "X" here if English language Translation is attached.